Technical Analysis for ARDM - Aradigm Corporation

Grade Last Price % Change Price Change
grade F 0.5475 36.88% 0.15
ARDM closed down 76.0 percent on Tuesday, February 19, 2019, on 2.91 times normal volume. The bears made the stock sink to a new 52-week low.

Earnings due: Mar 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Up
See historical ARDM trend table...

Date Alert Name Type % Chg
Feb 19 Fell Below 20 DMA Bearish 356.25%
Feb 19 New 52 Week Closing Low Bearish 356.25%
Feb 19 Expansion Breakdown Bearish Swing Setup 356.25%
Feb 19 Wide Range Bar Range Expansion 356.25%
Feb 19 New 52 Week Low Weakness 356.25%
Feb 19 Wide Bands Range Expansion 356.25%
Feb 19 Below Lower BB Weakness 356.25%
Feb 19 Gapped Down Weakness 356.25%
Feb 19 Lower Bollinger Band Touch Weakness 356.25%
Feb 8 Upper Bollinger Band Walk Strength 9.50%

Older signals for ARDM ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Aradigm Corporation, a specialty pharmaceutical company, focuses on the development and commercialization of drugs delivered by inhalation for the treatment and prevention of respiratory diseases by pulmonologists. The company's lead development candidates include Pulmaquin (ARD-3150) and Lipoquin (ARD-3100), which completed Phase IIb clinical trials for the management of infections associated with the severe respiratory diseases, such as non-cystic fibrosis bronchiectasis (BE) and cystic fibrosis (CF). Its products under development also comprise ARD-1100, a liposomal ciprofloxacin for the treatment of inhalation anthrax and other biodefense purposes; and ARD-1600, an inhaled nicotine product for smoking cessation. The company has a collaboration agreement with Oregon State University. Aradigm Corporation was founded in 1991 and is headquartered in Hayward, California.
Medicine Medical Specialties Pharmaceutical Organ Systems Cystic Fibrosis Infections Respiratory Diseases Pulmonology Anthrax Bronchiectasis Lung
Is ARDM a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 2.45
52 Week Low 0.0701
Average Volume 185,640
200-Day Moving Average 1.2027
50-Day Moving Average 0.6356
20-Day Moving Average 0.386
10-Day Moving Average 0.4349
Average True Range 0.1368
ADX 19.01
+DI 19.062
-DI 36.15
Chandelier Exit (Long, 3 ATRs ) 0.2396
Chandelier Exit (Short, 3 ATRs ) 0.4805
Upper Bollinger Band 0.5975
Lower Bollinger Band 0.1745
Percent B (%b) -0.13
BandWidth 109.585492
MACD Line -0.0527
MACD Signal Line -0.0651
MACD Histogram 0.0124
Fundamentals Value
Market Cap 1.73 Million
Num Shares 14.4 Million
EPS -1.27
Price-to-Earnings (P/E) Ratio -0.09
Price-to-Sales 6.50
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.54
Resistance 3 (R3) 0.57 0.46 0.47
Resistance 2 (R2) 0.46 0.35 0.44 0.45
Resistance 1 (R1) 0.29 0.29 0.24 0.26 0.42
Pivot Point 0.18 0.18 0.15 0.17 0.18
Support 1 (S1) 0.01 0.07 -0.04 -0.02 -0.18
Support 2 (S2) -0.10 0.01 -0.11 -0.21
Support 3 (S3) -0.27 -0.10 -0.23
Support 4 (S4) -0.30